The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital

被引：6

作者：

Fachini, Roberta Maria ^{[1
]}

Fontao-Wendel, Rita ^{[1
]}

Achkar, Ruth ^{[1
]}

Scuracchio, Patricia ^{[1
]}

Brito, Mayra ^{[1
]}

Amaral, Marcelo ^{[1
]}

Wendel, Silvano ^{[1
]}

机构：

[1] Hosp Sirio Libanes Blood Bank, BR-01308050 Sao Paulo, Brazil

来源：

PATHOGENS | 2021年 / 10卷 / 11期

关键词：

pathogen reduction; blood safety; platelet transfusion; INTERCEPT; plasma; BACTERIAL-CONTAMINATION; PLATELET COMPONENTS; REDUCED PLATELETS; BLOOD COMPONENTS; TRANSFUSION; PREVENTION; ULTRAVIOLET; AMOTOSALEN; SAFETY; EFFICACY;

D O I：

10.3390/pathogens10111499

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

(1) Background: We reviewed the logistics of the implementation of pathogen reduction (PR) using the INTERCEPT Blood System (TM) for platelets and the experience with routine use and clinical outcomes in the patient population at the Sirio-Libanes Hospital of Sao Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including pathogen reduced (PR-PC) production, inventory management, discard rates, blood utilization, and clinical outcomes were analyzed over the 40 months before and after PR implementation. Age distribution and wastage rates were compared over the 10 months before and after approval for PR-PC to be stored for up to seven days. (3) Results: A 100% PR-PC inventory was achieved by increasing double apheresis collections and production of double doses using pools of two single apheresis units. Discard rates decreased from 6% to 3% after PR implementation and further decreased to 1.2% after seven-day storage extension for PR-PCs. The blood utilization remained stable, with no increase in component utilization. A significant decrease in adverse transfusion events was observed after the PR implementation. (4) Conclusion: Our experience demonstrates the feasibility for Brazilian blood centers to achieve a 100% PR-PC inventory. All patients at our hospital received PR-PC and showed no increase in blood component utilization and decreased rates of adverse transfusion reactions.

引用

页数：14

共 49 条

[1]

[Anonymous], 2001, GUIDANCE IND

[2] Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) [J].

Atreya, Chintamani ;

Glynn, Simone ;

Busch, Michael ;

Kleinman, Steve ;

Snyder, Edward ;

Rutter, Sara ;

AuBuchon, James ;

Flegel, Willy ;

Reeve, David ;

Devine, Dana ;

Cohn, Claudia ;

Custer, Brian ;

Goodrich, Raymond ;

Benjamin, Richard J. ;

Razatos, Anna ;

Cancelas, Jose ;

Wagner, Stephen ;

Maclean, Michelle ;

Gelderman, Monique ;

Cap, Andrew ;

Ness, Paul .

TRANSFUSION, 2019, 59 (09) :3002-3025

[3] Platelet storage duration and its clinical and transfusion outcomes: a systematic review\ [J].

Aubron, Cecile ;

Flint, Andrew W. J. ;

Ozier, Yves ;

McQuilten, Zoe .

CRITICAL CARE, 2018, 22

[4] Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma [J].

Azhar, Esam I. ;

Hindawi, Salwa I. ;

El-Kafrawy, Sherif A. ;

Hassan, Ahmed M. ;

Tolah, Ahmed M. ;

Alandijany, Thamir A. ;

Bajrai, Leena H. ;

Damanhouri, Ghazi A. .

VOX SANGUINIS, 2021, 116 (06) :673-681

[5] INTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without) clinical refractoriness in published studies [J].

Benjamin, Richard J. ;

Corash, Laurence ;

Norris, Philip J. .

TRANSFUSION, 2020, 60 (04) :881-882

[6] Amotosalen and ultraviolet-A treated platelets and plasma are safe and efficacious in active hemorrhage [J].

Benjamin, Richard J. ;

Carter, Kent L. ;

Corash, Laurence .

TRANSFUSION, 2016, 56 (10) :2649-2650

[7] Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions [J].

Bloch, Evan M. ;

Marshall, Christi E. ;

Boyd, Joan S. ;

Shifflett, Lisa ;

Tobian, Aaron A. R. ;

Gehrie, Eric A. ;

Ness, Paul M. .

TRANSFUSION, 2018, 58 (07) :1647-1653

[8] Residual risk of bacterial contamination: what are the options? [J].

Bloch, Evan M. .

TRANSFUSION, 2017, 57 (10) :2289-2292

[9] Prevention of transfusion-transmitted infections [J].

Busch, Michael P. ;

Bloch, Evan M. ;

Kleinman, Steven .

BLOOD, 2019, 133 (17) :1854-1864

[10] Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease [J].

Castro, Grace ;

Merkel, Patricia A. ;

Giclas, Hannah E. ;

Gibula, Andrew ;

Andersen, Gillian E. ;

Corash, Laurence M. ;

Lin, Jin Sying ;

Green, Jennifer ;

Knight, Vijaya ;

Stassinopoulos, Adonis .

TRANSFUSION, 2018, 58 (06) :1506-1515

← 1 2 3 4 5 →